enforce. . .such regulations as in his [the Secretary's] Judgment are 
necessary to prevent the introduction, transmission, or spread of 
communicable diseases. . .from one State. . .into any other State. . . ." 
Both DOT and CDC, in implementing the HMTA and section 361 with 
respect to biological products, have essentially aimed just at imposing 
labeling, packaging, and shipping requirements. This approach is in 
line with the statutory language which emphasizes movement. Section 361 
could perhaps be interpreted more broadly to serve as legal support for 
more comprehensive regulation. However, in order to do so there would 
presumably have to be a reasonable basis for concluding that the products 
of all recombinant DNA research cause or may cause human disease. Such 
a conclusion would undoubtedly be tenuous at best, and it is unlikely 
that resulting requirements could be effectively Imposed and enforced. 
Under section 353 of the PHS Act, however, CDC does have general 
authority to license and control the operation of clinical laboratories. 
Vhile this authority would not in general have applicability to research 
laboratories, CDC's experience in Implementing this legislation, which 
imposes comprehensive requirements on clinical laboratories, could be 
of value in the implementation of any new legislation needed to regulate 
laboratories conducting recombinant DNA research. 
OTHER ISSUES CONSIDERED 
1. In the event new legislation is sought, a model for the 
35 
[315] 
